Role of In-silico modeling in Drug Development for Inhalation Treatment

In-silico modeling is increasingly being used for simulation of adsorption, distribution, metabolization, and excretion to predict the curve of plasma levels and bioavailability of oral drug formulations. Computational models for the prediction of other application routes are less common. Preliminary data shows that GastroPlus simulation software appears suitable for prediction of drug plasma levels of inhaled drugs in healthy individuals. Since also the influence of physiological variations on lung deposition can be simulated, this software could be a valuable tool in the screening of promising formulations. Figure 1: Compartment model used in GastroPlusTM. Deposition of inhaled particles is given for extrathoracical compartment (ET), trachea and large bronchi (BB), bronchioles (bb), and the alveolar interstitial space (AI). BB, bb, and AI together are representing total lung deposition. Citation: Shengqian Wu, Salar-Behzadi S, Fröhlich E (2013) Role of In-silico modeling in Drug Development for Inhalation Treatment. J Mol Pharm Org Process Res 1: 106. doi: 10.4172/2329-9053.1000106